Biocon Biologics Ltd (BBL), a global, fully integrated biosimilars company and a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The announcement will be made at the 44th Annual JP Morgan Healthcare Conference in San Francisco, where the company will also outline its proposed integration as a wholly owned subsidiary of Biocon Limited and discuss the growing role of biosimilars in improving access to affordable cancer treatments worldwide.
The new oncology assets include biosimilar versions of Trastuzumab/Hyaluronidase (Herceptin® SC / Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®). With the addition of these therapies—including two PD-1 inhibitors—Biocon Biologics will offer one of the industry’s broadest oncology biosimilar portfolios. These products address some of the world’s highest-revenue biologics, many of which are expected to lose exclusivity over the next five years. Together, the company’s oncology portfolio represents a market opportunity exceeding $75 billion, accounting for nearly 35% of the global oncology pharmaceutical market.
Biocon Limited has also announced plans to integrate Biocon Biologics as a wholly owned subsidiary, with completion targeted by March 31, 2026, subject to regulatory approvals. The move is expected to simplify the corporate structure, enhance global commercial leverage, and strengthen Biocon’s leadership across diabetes, oncology, and immunology. Post-integration, Biocon will uniquely offer biosimilar insulins alongside complex peptide generics, including GLP-1 therapies, addressing the full continuum of diabetes care.
Commenting on the development, Shreehas Tambe, CEO & Managing Director of Biocon Biologics, said the integration will significantly enhance the company’s ability to deliver high-quality, affordable medicines at scale. He added that Biocon Biologics’ science-led R&D strategy and expanding oncology pipeline underscore its commitment to addressing unmet patient needs globally. Mr. Tambe will present at the JP Morgan Healthcare Conference on January 15, 2026, and participate in an industry fireside discussion focused on the future of biosimilars.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars company focused on improving healthcare access and outcomes worldwide. Leveraging end-to-end capabilities from research to commercialization, the company currently serves more than 6.3 million patients across over 120 countries by providing high-quality biosimilars at affordable costs.
Biocon Biologics has commercialized 10 biosimilars to date, with products available in key emerging markets as well as advanced markets including the United States, Europe, Canada, Australia, and Japan. Its pipeline includes more than 20 biosimilar assets spanning diabetology, oncology, immunology, ophthalmology, bone health, and other non-communicable diseases. The company is also committed to advancing environmental, social, and governance priorities aligned with the United Nations Sustainable Development Goals.
